2 enrolling by invitation. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Enrolling by invitation 2 |
Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis. 10mg QY201 Placebo tablet, 20mg QY201 Placebo tablet, 10mg QY201 tablet - Atopic Dermatitis (AD) | Phase 3 | Enrolling by invitation | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | 460 | 2025-03-12 | 2025-09-18 |
| A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis, Eczema | Phase 3 | Enrolling by invitation | Eli Lilly and Company | 338 | 2023-03-09 | 2026-10-26 |
Eczema (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Dermatitis (2) · Genetic Diseases, Inborn (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2) · Skin Diseases (2) · Skin Diseases, Eczematous (2) · Skin Diseases, Genetic (2) · Skin and Connective Tissue Diseases (2)
lebrikizumab (1)
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (1) · Eli Lilly and Company (1)
Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Japan (1) · Mexico (1) · Poland (1) · Spain (1) · Taiwan (1) · United States (1)